Immuno-Oncology | Specialty

FDA Approves Pembrolizumab/Axitinib Combo for Frontline RCC

April 22nd 2019

The FDA has approved pembrolizumab in combination with axitinib for the frontline treatment of patients with advanced renal cell carcinoma.

Dr. Quinn on Current State of Biomarkers in RCC

April 19th 2019

David I. Quinn, MD, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Keck School of Medicine, discusses the current state of biomarkers in renal cell carcinoma.

Durvalumab Results Spark Hope for Progress in Advanced NSCLC

April 16th 2019

During an OncLive Peer Exchange® discussion, moderator Mark A. Socinski, MD, and other lung cancer experts from across the United States discuss what, in this context, the PACIFIC trial results mean for practicing oncologists and their patients.

Dr. Balar on Improved Outlook in Metastatic Bladder Cancer

April 16th 2019

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone's Perlmutter Cancer Center, discusses the improved outlook for patients with metastatic bladder cancer.

Dr. Socinski on New Applications of Immunotherapy in NSCLC

April 16th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses new applications for immunotherapy in the treatment of patients with non–small cell lung cancer.

Dr. Figlin on Next Steps for Research in mRCC

April 16th 2019

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses next steps for research in the treatment of patients with metastatic renal cell carcinoma.

Figlin Highlights Immunotherapy Developments in RCC

April 15th 2019

Robert A. Figlin, MD, highlights advances made with immunotherapy in renal cell carcinoma and sheds light on the challenges that remain.

FDA Approves Erdafitinib for Bladder Cancer

April 12th 2019

The FDA has approved erdafitinib (Balversa) for the treatment of adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.

Dr. Choueiri on Atezolizumab Plus Bevacizumab in Non-Clear Cell RCC

April 11th 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses atezolizumab plus bevacizumab in patients with non–clear cell renal cell carcinoma.

PD-L1 Expression Does Not Impact QoL With Durvalumab in NSCLC

April 11th 2019

Patient reported outcomes according to PD-L1 expression did not show clinically meaningful differences in quality of life with either durvalumab or placebo in patients with stage III non–small cell lung cancer, according to a retrospective analysis of the phase III PACIFIC study.

Dr. Bochner on Promising Targets and Pathways in Bladder Cancer

April 8th 2019

Bernard H. Bochner, MD, FACS, Sir Murray F. Brennan Chair in Surgery, Memorial Sloan Kettering Cancer Center, discusses promising targets and pathways in the treatment of patients with bladder cancer.

Dr. Dreicer on Biomarkers of Response to Immunotherapy in Urothelial Cancer

April 5th 2019

Robert Dreicer, MD, professor of medicine and urology, University of Virginia Health System, section chief, Medical Oncology, deputy director, UVA Cancer Center, discusses biomarkers of response to immunotherapy in patients with metastatic urothelial cancer.

Enfortumab Vedotin Active After Chemo and Immunotherapy in Urothelial Carcinoma

March 28th 2019

Enfortumab vedotin showed strong clinical activity in patients with locally advanced or metastatic urothelial carcinoma who previously received both platinum-containing chemotherapy and immune checkpoint therapy, according to topline results from the pivotal phase II EV-201 trial.

PD-L1 Status Central to NCCN Update for Frontline NSCLC Immunotherapy

March 23rd 2019

PD-L1 testing, while an imperfect biomarker, is the key determinant of frontline immunotherapy selection in the NCCN guidelines for non–small cell lung cancer.

Chemokine Offers Tempting Target in Tumor Niche

March 19th 2019

Chemokine receptor type 2, a major recruiter of circulating monocytes that subsequently develop into a protumoral type of macrophage within the tumor microenvironment, has emerged as a promising therapeutic target.

Dr. Jahanzeb on Immunotherapy in Oncogene-Driven NSCLC

March 19th 2019

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, at University of Miami Miller School of Medicine, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer.

Dr. Garon on Immunotherapy in Stage III Unresectable NSCLC

March 14th 2019

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the promise of immunotherapy in the treatment of patients with stage III unresectable non–small cell lung cancer.

Dr. McDermott on Single-Agent Versus Combination Immunotherapy in RCC

March 14th 2019

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent versus combination immunotherapy in the treatment of patients with renal cell carcinoma.

Frontline Pembrolizumab Regimen Approved in Europe for Squamous NSCLC

March 14th 2019

The European Commission has approved pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel for the frontline treatment of patients with metastatic squamous non–small cell lung cancer.

Rizvi Highlights Impact of Immunotherapy and Next Steps NSCLC

March 12th 2019

Naiyer A. Rizvi, MD, highlights the progress made with immunotherapy in patients with NSCLC and shed light on where further research needs to go to move the needle forward.